Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling-Reference-Cited by-同舟云学术

Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling

Published:2021-02 Issue: Volume:157 Page:105617
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Effinger Angela^ORCID,O'Driscoll Caitriona M.,McAllister Mark,Fotaki Nikoletta

Funder

Horizon 2020

Horizon 2020 Framework Programme

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference82 articles.

1. Prediction of oral absorption of cinnarizine–a highly supersaturating poorly soluble weak base with borderline permeability;Berlin;Eur J Pharm Biopharm,2014

2. Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery;Bharate;Comb Chem High Throughput Screen,2016

3. Mechanisms of diarrhea in inflammatory bowel diseases;Binder;Ann N Y Acad Sci,2009

4. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model;Bjorkman;J Pharm Sci,2001

5. The burden of inflammatory bowel disease in Europe;Burisch;J Crohns Colitis,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview on recent approaches for colonic drug delivery systems;Pharmaceutical Development and Technology;2024-06-20

2. The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling;AAPS PharmSciTech;2024-04-11

3. Colon-targeted delivery systems of budesonide as second-line therapy in inflammatory bowel disease;Journal of Drug Delivery Science and Technology;2024-03

4. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling;Pharmaceutics;2023-08-30

5. Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole;Pharmaceutics;2023-03-23